Purpose RBS is a sterile inflammatory condition in the post-implant-based breast reconstruction setting characterised by local erythematous skin changes. RBS-associated erythema is generally confined to areas where a mesh is present and usually appears days to weeks after reconstruction. The study highlights the unpredictable nature of RBS, yet provides reassurance as to its clinical course, which should remain short-lived and self-limiting. Methodology We report eight patients with RBS after breast implant reconstruction for prophylactic risk reduction or treatment of breast cancer. Results The average age of the patients was 40.5 years (range 26-63 years). Average body mass index (BMI) was 27. Two patients had co-morbidities, namely type 2 diabetes mellitus and psoriasis. Seven underwent pre-pectoral reconstruction and one sub-pectoral. Six used mesh (TiLOOP), and one used acellular dermal matrix. Six had direct-to-implant reconstruction, while two had two-stage reconstruction. Mean time to develop RBS was 28.6 days. All patients presented with erythema, while six presented with itch. Five resolved spontaneously, three were treated with corticosteroids, four with anti-histamines and five with antibiotics. Most cases eventually resolved (n=6), while two developed chronic seroma and required exchange of implants. Conclusion RBS can occur in any type of dual-plane or pre-pectoral implant reconstruction, regardless of mesh or implant used. Further studies should focus on other factors besides mesh or implants.